» Articles » PMID: 30883859

Emulating a Trial of Joint Dynamic Strategies: An Application to Monitoring and Treatment of HIV-positive Individuals

Abstract

Decisions about when to start or switch a therapy often depend on the frequency with which individuals are monitored or tested. For example, the optimal time to switch antiretroviral therapy depends on the frequency with which HIV-positive individuals have HIV RNA measured. This paper describes an approach to use observational data for the comparison of joint monitoring and treatment strategies and applies the method to a clinically relevant question in HIV research: when can monitoring frequency be decreased and when should individuals switch from a first-line treatment regimen to a new regimen? We outline the target trial that would compare the dynamic strategies of interest and then describe how to emulate it using data from HIV-positive individuals included in the HIV-CAUSAL Collaboration and the Centers for AIDS Research Network of Integrated Clinical Systems. When, as in our example, few individuals follow the dynamic strategies of interest over long periods of follow-up, we describe how to leverage an additional assumption: no direct effect of monitoring on the outcome of interest. We compare our results with and without the "no direct effect" assumption. We found little differences on survival and AIDS-free survival between strategies where monitoring frequency was decreased at a CD4 threshold of 350 cells/μl compared with 500 cells/μl and where treatment was switched at an HIV-RNA threshold of 1000 copies/ml compared with 200 copies/ml. The "no direct effect" assumption resulted in efficiency improvements for the risk difference estimates ranging from an 7- to 53-fold increase in the effective sample size.

Citing Articles

Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation.

Krebs E, Weymann D, Ho C, Weppler A, Bosdet I, Karsan A JCO Precis Oncol. 2025; 9:e2400631.

PMID: 39983079 PMC: 11867803. DOI: 10.1200/PO-24-00631.


Comparative Effectiveness Analysis of Lumpectomy and Mastectomy for Elderly Female Breast Cancer Patients: A Deep Learning-based Big Data Analysis.

Wang J, Zhang S, Yi H, Ma S Yale J Biol Med. 2023; 96(3):327-346.

PMID: 37781001 PMC: 10524818. DOI: 10.59249/IAJU7580.


Reporting of Observational Studies Explicitly Aiming to Emulate Randomized Trials: A Systematic Review.

Hansford H, Cashin A, Jones M, Swanson S, Islam N, Douglas S JAMA Netw Open. 2023; 6(9):e2336023.

PMID: 37755828 PMC: 10534275. DOI: 10.1001/jamanetworkopen.2023.36023.


Development of the TrAnsparent ReportinG of observational studies Emulating a Target trial (TARGET) guideline.

Hansford H, Cashin A, Jones M, Swanson S, Islam N, Dahabreh I BMJ Open. 2023; 13(9):e074626.

PMID: 37699620 PMC: 10503363. DOI: 10.1136/bmjopen-2023-074626.


Implementation of the trial emulation approach in medical research: a scoping review.

Scola G, Chis Ster A, Bean D, Pareek N, Emsley R, Landau S BMC Med Res Methodol. 2023; 23(1):186.

PMID: 37587484 PMC: 10428565. DOI: 10.1186/s12874-023-02000-9.


References
1.
Cain L, Saag M, Petersen M, May M, Ingle S, Logan R . Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. Int J Epidemiol. 2016; 45(6):2038-2049. PMC: 5841611. DOI: 10.1093/ije/dyv295. View

2.
Hernan M . The hazards of hazard ratios. Epidemiology. 2009; 21(1):13-5. PMC: 3653612. DOI: 10.1097/EDE.0b013e3181c1ea43. View

3.
Hernan M, Hernandez-Diaz S, Robins J . A structural approach to selection bias. Epidemiology. 2004; 15(5):615-25. DOI: 10.1097/01.ede.0000135174.63482.43. View

4.
Asboe D, Aitken C, Boffito M, Booth C, Cane P, Fakoya A . British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med. 2011; 13(1):1-44. DOI: 10.1111/j.1468-1293.2011.00971.x. View

5.
Caniglia E, Sabin C, Robins J, Logan R, Cain L, Abgrall S . When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study. J Acquir Immune Defic Syndr. 2016; 72(2):214-21. PMC: 4866894. DOI: 10.1097/QAI.0000000000000956. View